Search

everythinglearnresearchcommunity

for

Search:↓

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

A new therapy for a skin blistering condition has not been developed yet.

Baricitinib is the most effective treatment for alopecia areata.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Anti-CD19 therapy may help treat SLE and NMOSD.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Cedrol promotes hair growth better than baricitinib by regulating immune cells.

Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.

Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Ruxolitinib can cause a delayed skin reaction on the nose.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.